Try our beta test site
53 studies found for:    "Paroxysmal nocturnal hemoglobinuria"
Show Display Options
Rank Status Study
21 Completed Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria
Condition: Paroxysmal Hemoglobinuria, Nocturnal
Intervention: Drug: Eculizumab
22 Active, not recruiting Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria
Conditions: Paroxysmal Nocturnal Hemoglobinuria;   Hemoglobinuria;   Hemoglobinuria, Paroxysmal;   Proteinuria;   Urination Disorders;   Thrombosis;   Bone Marrow Failure;   Aplastic Anemia,;   Anemia, Hemolytic
Interventions: Drug: Levamisole+cyclosporin A+Glucocorticoids;   Drug: cyclosporin A+Glucocorticoids;   Drug: Glucocorticoids
23 Unknown  Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Conditions: Aplastic Anemia;   Paroxysmal Hemoglobinuria, Nocturnal
Interventions: Drug: cyclophosphamide;   Drug: filgrastim
24 Active, not recruiting Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)
Conditions: Paroxysmal Nocturnal Hemoglobinuria;   Hemoglobinuria;   Hemoglobinuria, Paroxysmal;   Proteinuria;   Urination Disorders;   Thrombosis;   Bone Marrow Failure;   Aplastic Anemia,;   Anemia, Hemolytic
Interventions: Drug: Levamisole+cyclosporin A+Glucocorticoids;   Drug: cyclosporin A+Glucocorticoids;   Drug: Glucocorticoids
25 Completed Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria
Condition: Hemoglobinuria, Paroxysmal
Intervention: Drug: Eculizumab
26 Completed The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH)
Condition: Hemoglobinuria, Paroxysmal
Intervention:
27 Completed Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria
Condition: Leukemia
Intervention: Biological: eculizumab
28 Completed Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent PNH Subjects
Condition: Hemoglobinuria, Paroxysmal
Intervention: Drug: Eculizumab
29 Recruiting Assessment of the Mutation of Pig-A Gene as Biomarker of Genotoxic Exposure in Humans
Condition: Patient With Breast Cancer
Intervention: Genetic: blood samples
30 Completed Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes
Condition: Hemoglobinuria
Intervention:
31 Recruiting Unrelated And Partially Matched Related Donor PSCT w/ TCR αβ Depletion for Patients With BMF
Conditions: Acquired Aplastic Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Inherited Bone Marrow Failure Syndromes
Intervention: Device: CliniMACs
32 Approved for marketing The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol
Condition: Hemoglobinuria, Paroxysmal
Intervention: Drug: eculizumab
33 Completed Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab
Condition: Hemoglobinuria, Paroxysmal
Intervention: Drug: eculizumab
34 Completed Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
Condition: Hemoglobinuria, Paroxysmal
Intervention: Drug: eculizumab
35 Unknown  Multicenter Retrospective Analysis About the Clinical Characteristics of Korean Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
Condition: Hemoglobinuria, Paroxysmal
Intervention:
36 Completed Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome
Conditions: Leukemia;   Myelodysplastic Syndromes;   Nonmalignant Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria
Intervention: Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
37 Completed
Has Results
Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
Conditions: Sickle Cell Anemia;   Severe Aplastic Anemia;   Paroxysmal Nocturnal Hemoglobinuria (PNH);   Pure Red Cell Aplasia
Intervention: Drug: Campath, Chemo and/or TBI Allo SCT
38 Completed Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders
Conditions: Allogeneic Stem Cell Transplant;   Leukemia;   Non-Hodgkins;   Lymphoblastic Lymphoma;   Myelodysplastic Syndrome;   Paroxysmal Nocturnal Hemoglobinuria (PNH)
Intervention: Drug: cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
39 Recruiting Unrelated Donor Stem Cell Transplantation
Conditions: Severe Aplastic Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Syndromes;   Chronic Myelogenous Leukemia;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Large Granulocytic Leukemia
Intervention: Procedure: Allogeneic transplantation
40 Unknown  Nonmyeloablative Allogeneic Transplant
Conditions: Aplastic Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Chronic Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Mantle Cell Lymphoma;   Multiple Myeloma;   Waldenstrom Macroglobulinemia;   Breast Cancer;   Renal Cell Carcinoma;   Melanoma;   Sarcoma;   Ovarian Cancer;   Thymoma
Intervention: Procedure: Nonmyeloablative Allogeneic Transplant

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-53) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.